Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Leukemia, Myeloid, Acute 4Uveal Melanoma 1Triple Negative Breast Neoplasms 1Neoplasm, Residual 1Liposarcoma 1Hematologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid and Hematological TP53wt Tumors 1Adenocarcinoma 1

Interventions

Gemcitabine 22Fluorouracil 14Oxaliplatin 13Capecitabine 13Paclitaxel 12pembrolizumab 11Cisplatin 11Carboplatin 11Pemetrexed 10Leucovorin 9130-nm albumin-bound paclitaxel 9Ramucirumab 8zolbetuximab 7Albumin-Bound Paclitaxel 7trastuzumab deruxtecan 6Drug Therapy 5Docetaxel 5Bevacizumab 5Nivolumab 4Irinotecan 4vandetanib 3cemiplimab 3Everolimus 3EC145 3tislelizumab 2technetium 99m etarfolatide 2spartalizumab 2pralsetinib 2osimertinib 2nimotuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma × siremadlin × Clear all
NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Novartis

Phase 1 Completed
298 enrolled
BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡